Collaboration Expands Vaccine Manufacturing Capacity

Bavarian Nordic, a Denmark-based biotech firm, has announced a significant partnership with the Serum Institute of India (SII) for its MVA-BN mpox vaccine. This agreement involves a technology transfer to enable SII to supply the vaccine to the Indian market and potentially perform contract manufacturing for global distribution, enhancing capacity to address outbreaks.

The license agreement operates on a profit-sharing model, with SII responsible for regulatory approvals in India. Both parties will cover their own technology transfer costs. Bavarian Nordic is also exploring additional partnerships, including with African manufacturers, to ensure equitable access to the vaccine.